Cargando…
Clinical importance of IL-22 cascade in IBD
IL-22 is a relatively new cytokine that is characterized by several unique biological properties. In the intestines, the effect of IL-22 is restricted mainly to non-lymphoid cells such as epithelial cells. Interestingly, the expression pattern and major cellular source of IL-22 have distinct differe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866830/ https://www.ncbi.nlm.nih.gov/pubmed/29075900 http://dx.doi.org/10.1007/s00535-017-1401-7 |
_version_ | 1783308878506622976 |
---|---|
author | Mizoguchi, Atsushi Yano, Arisa Himuro, Hidetomo Ezaki, Yui Sadanaga, Takayuki Mizoguchi, Emiko |
author_facet | Mizoguchi, Atsushi Yano, Arisa Himuro, Hidetomo Ezaki, Yui Sadanaga, Takayuki Mizoguchi, Emiko |
author_sort | Mizoguchi, Atsushi |
collection | PubMed |
description | IL-22 is a relatively new cytokine that is characterized by several unique biological properties. In the intestines, the effect of IL-22 is restricted mainly to non-lymphoid cells such as epithelial cells. Interestingly, the expression pattern and major cellular source of IL-22 have distinct difference between large and small intestines. IL-22 possesses an ability to constitutively activate STAT3 for promoting epithelial cell regeneration and reinforcing mucosal barrier integrity through stimulating the expression of anti-bacterial peptide and mucins. Of note, IL-22 is characterized as a two-faced cytokine that can play not only protective but also deleterious roles in the intestinal inflammation depending on the cytokine environment such as the expression levels of IL-23, T-bet, and IL-22 binding protein. Most importantly, clinical relevance of IL-22 to inflammatory bowel disease has been well highlighted. Mucosal healing, which represents the current therapeutic goal for IBD, can be induced by IL-22. Indeed, indigo naturalis, which can activate IL-22 pathway through Ahr, has been shown in a clinical trial to exhibit a strong therapeutic effect on ulcerative colitis. Despite the beneficial effect of IL-22, continuous activation of the IL-22 pathway increases the risk of colitis-associated cancer, particularly in patients with an extended history of IBD. This review article discusses how IL-22 regulates colitis, how beneficial versus deleterious effects of IL-22 is determined, and why IL-22 represents a promising target for IBD therapy. |
format | Online Article Text |
id | pubmed-5866830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Japan |
record_format | MEDLINE/PubMed |
spelling | pubmed-58668302018-03-27 Clinical importance of IL-22 cascade in IBD Mizoguchi, Atsushi Yano, Arisa Himuro, Hidetomo Ezaki, Yui Sadanaga, Takayuki Mizoguchi, Emiko J Gastroenterol Review IL-22 is a relatively new cytokine that is characterized by several unique biological properties. In the intestines, the effect of IL-22 is restricted mainly to non-lymphoid cells such as epithelial cells. Interestingly, the expression pattern and major cellular source of IL-22 have distinct difference between large and small intestines. IL-22 possesses an ability to constitutively activate STAT3 for promoting epithelial cell regeneration and reinforcing mucosal barrier integrity through stimulating the expression of anti-bacterial peptide and mucins. Of note, IL-22 is characterized as a two-faced cytokine that can play not only protective but also deleterious roles in the intestinal inflammation depending on the cytokine environment such as the expression levels of IL-23, T-bet, and IL-22 binding protein. Most importantly, clinical relevance of IL-22 to inflammatory bowel disease has been well highlighted. Mucosal healing, which represents the current therapeutic goal for IBD, can be induced by IL-22. Indeed, indigo naturalis, which can activate IL-22 pathway through Ahr, has been shown in a clinical trial to exhibit a strong therapeutic effect on ulcerative colitis. Despite the beneficial effect of IL-22, continuous activation of the IL-22 pathway increases the risk of colitis-associated cancer, particularly in patients with an extended history of IBD. This review article discusses how IL-22 regulates colitis, how beneficial versus deleterious effects of IL-22 is determined, and why IL-22 represents a promising target for IBD therapy. Springer Japan 2017-10-26 2018 /pmc/articles/PMC5866830/ /pubmed/29075900 http://dx.doi.org/10.1007/s00535-017-1401-7 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Mizoguchi, Atsushi Yano, Arisa Himuro, Hidetomo Ezaki, Yui Sadanaga, Takayuki Mizoguchi, Emiko Clinical importance of IL-22 cascade in IBD |
title | Clinical importance of IL-22 cascade in IBD |
title_full | Clinical importance of IL-22 cascade in IBD |
title_fullStr | Clinical importance of IL-22 cascade in IBD |
title_full_unstemmed | Clinical importance of IL-22 cascade in IBD |
title_short | Clinical importance of IL-22 cascade in IBD |
title_sort | clinical importance of il-22 cascade in ibd |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866830/ https://www.ncbi.nlm.nih.gov/pubmed/29075900 http://dx.doi.org/10.1007/s00535-017-1401-7 |
work_keys_str_mv | AT mizoguchiatsushi clinicalimportanceofil22cascadeinibd AT yanoarisa clinicalimportanceofil22cascadeinibd AT himurohidetomo clinicalimportanceofil22cascadeinibd AT ezakiyui clinicalimportanceofil22cascadeinibd AT sadanagatakayuki clinicalimportanceofil22cascadeinibd AT mizoguchiemiko clinicalimportanceofil22cascadeinibd |